Literature DB >> 17975885

Human glutathione S-transferase-mediated glutathione conjugation of curcumin and efflux of these conjugates in Caco-2 cells.

Mustafa Usta1, Heleen M Wortelboer, Jacques Vervoort, Marelle G Boersma, Ivonne M C M Rietjens, Peter J van Bladeren, Nicole H P Cnubben.   

Abstract

Curcumin, an alpha,beta-unsaturated carbonyl compound, reacts with glutathione, leading to the formation of two monoglutathionyl curcumin conjugates. In the present study, the structures of both glutathione conjugates of curcumin were identified by LC-MS and one- and two-dimensional 1H NMR analysis, and their formation in incubations with human intestinal and liver cytosol and purified human glutathione S-transferases and also in human Caco-2 cells was characterized. The results obtained demonstrate the site for glutathione conjugation to be the C1 atom, leading to two diastereoisomeric monoglutathionyl curcumin conjugates (CURSG-1 and CURSG-2). The formation of both glutathionyl conjugates appeared to be reversible. The monoglutathionyl curcumin conjugates decompose with a t1/2 of about 4 h to curcumin and other unidentified degradation products. Both human intestinal and liver cytosol catalyzed curcumin glutathione conjugation. At saturating substrate concentrations, human GSTM1a-1a and GSTA1-1 are shown to be especially active in the formation of CURSG-1, whereas GSTP1-1 and GSTA2-2 have no preference for the formation of CURSG-1 or CURSG-2. GSTT1-1 hardly catalyzes the glutathione conjugation of curcumin. In the Caco-2 human intestinal monolayer transwell model, CURSG-1 and CURSG-2 were formed at a ratio of about 2:1 followed by their excretion, which appeared to be three times higher to the apical (lumen) side than to the basolateral (blood) side. Given that GSTM1a-1a and GSTP1-1 are present in the intestinal epithelial cells, it can be concluded that efficient glutathione conjugation of curcumin may already occur in the enterocytes, followed by an efficient excretion of these glutathione conjugates to the lumen, thereby reducing the bioavailability of (unconjugated) curcumin. In conclusion, the present study identifies the nature of the diastereoisomeric monoglutathionyl curcumin conjugates, CURSG-1 and CURSG-2 formed in biological systems, and reveals that conjugate formation is catalyzed by GSTM1a-1a, GSTA1-1, and/or GSTP1-1 with different stereoselective preference. The formation of glutathione conjugates can already occur during intestinal transport, after which the monoglutathionyl conjugates are efficiently excreted to the intestinal lumen, thereby influencing the bioavailability of curcumin and, as a result, its beneficial biological effects.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17975885     DOI: 10.1021/tx7002245

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  9 in total

Review 1.  Curcumin nanoformulations: a future nanomedicine for cancer.

Authors:  Murali M Yallapu; Meena Jaggi; Subhash C Chauhan
Journal:  Drug Discov Today       Date:  2011-09-18       Impact factor: 7.851

2.  The role of turmerones on curcumin transportation and P-glycoprotein activities in intestinal Caco-2 cells.

Authors:  Grace G L Yue; Sau-Wan Cheng; Hua Yu; Zi-Sheng Xu; Julia K M Lee; Po-Ming Hon; Mavis Y H Lee; Edward J Kennelly; Gary Deng; Simon K Yeung; Barrie R Cassileth; Kwok-Pui Fung; Ping-Chung Leung; Clara B S Lau
Journal:  J Med Food       Date:  2011-12-19       Impact factor: 2.786

3.  Covalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition Reactions.

Authors:  Paul A Jackson; John C Widen; Daniel A Harki; Kay M Brummond
Journal:  J Med Chem       Date:  2016-12-20       Impact factor: 7.446

4.  A liquid chromatography-tandem mass spectrometric method for quantification of curcuminoids in cell medium and mouse plasma.

Authors:  U V R Vijaya Saradhi; Yonghua Ling; Jiang Wang; Ming Chiu; Eric B Schwartz; James R Fuchs; Kenneth K Chan; Zhongfa Liu
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2010-09-17       Impact factor: 3.205

Review 5.  Bringing Curcumin to the Clinic in Cancer Prevention: a Review of Strategies to Enhance Bioavailability and Efficacy.

Authors:  Rama I Mahran; Magda M Hagras; Duxin Sun; Dean E Brenner
Journal:  AAPS J       Date:  2016-10-25       Impact factor: 4.009

6.  Curcumin analog cytotoxicity against breast cancer cells: exploitation of a redox-dependent mechanism.

Authors:  Aiming Sun; Yang J Lu; Haipeng Hu; Mamoru Shoji; Dennis C Liotta; James P Snyder
Journal:  Bioorg Med Chem Lett       Date:  2009-10-08       Impact factor: 2.823

7.  Monocarbonyl curcumin analogues: heterocyclic pleiotropic kinase inhibitors that mediate anticancer properties.

Authors:  Andrew Brown; Qi Shi; Terry W Moore; Younghyoun Yoon; Andrew Prussia; Clinton Maddox; Dennis C Liotta; Hyunsuk Shim; James P Snyder
Journal:  J Med Chem       Date:  2013-04-23       Impact factor: 7.446

Review 8.  Development of Certain Protein Kinase Inhibitors with the Components from Traditional Chinese Medicine.

Authors:  Minghua Liu; Ge Zhao; Shousong Cao; Yangyang Zhang; Xiaofang Li; Xiukun Lin
Journal:  Front Pharmacol       Date:  2017-01-09       Impact factor: 5.810

Review 9.  Novel delivery system for natural products: Nano-curcumin formulations.

Authors:  Hamid Reza Rahimi; Reza Nedaeinia; Alireza Sepehri Shamloo; Shima Nikdoust; Reza Kazemi Oskuee
Journal:  Avicenna J Phytomed       Date:  2016 Jul-Aug
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.